Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients’ long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with highrisk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care.
Adjuvant treatment in biliary tract cancer / Andrea Palloni, Giorgio Frega, Stefania De Lorenzo, Alessandro Rizzo, Francesca Abbati, Marzia Deserti, Simona Tavolari, Giovanni Brandi. - In: TRANSLATIONAL CANCER RESEARCH. - ISSN 2219-6803. - ELETTRONICO. - 8:(2019), pp. 289-296. [10.21037/tcr.2018.08.17]
Adjuvant treatment in biliary tract cancer
Andrea Palloni;Giorgio Frega;Stefania De Lorenzo;Alessandro Rizzo;Francesca Abbati;Marzia Deserti;Simona Tavolari;Giovanni Brandi
2019
Abstract
Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients’ long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with highrisk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care.File | Dimensione | Formato | |
---|---|---|---|
Adjuvant treatment in biliary tract cancer.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
228.97 kB
Formato
Adobe PDF
|
228.97 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.